Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean amino oil and fennel?
Displaying drugs 451 - 475 of 14791 in total

Butaperazine

Butaperazine was approved in 1967 , and possibly discontinued in the 1980s .
Approved
Matched Description: … Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397]. …

Dibenzepin

Dibenzepin is approved for use in Europe.
Approved

Pitolisant

Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and …

Tapentadol

Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011....
Approved

Dimetotiazine

Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.
Approved

Clozapine

Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical". . This low affinity to dopamine receptors results in fewer extrapyramidal side effects,...
Approved
Matched Description: … side effects, notably gastrointestinal hypomotility and orthostatic hypotension. ... [A185747] However, its promiscuity toward the muscarinic and adrenergic receptors can result in other ... Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine …
Matched Categories: … Diazepines, Oxazepines, Thiazepines and Oxepines …

Benzatropine

Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of...
Approved
Matched Description: … It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the ... [A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500] ... an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and …

Disopyramide

A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Matched Description: … It also possesses some anticholinergic and local anesthetic properties. ... anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and …

Ezogabine

Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and …

Flunarizine

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … peripheral origin, and as an adjuvant in the therapy of epilepsy. ... Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 ... effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and …
Matched Categories: … Calcium-Regulating Hormones and Agents …

Nylidrin

Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional...
Approved
Matched Description: … known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and ... This effect may help to improve memory/judgment, improve walking ability, and support the healing of ... selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and …
Matched Categories: … Genito Urinary System and Sex Hormones …

Osimertinib

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Penbutolol

Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … penbutolol and other diuretics …

Drotaverine

Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia, parainfluenza, and ... symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and …
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives …

Buclizine

Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered...
Approved
Matched Description: … in the treatment of nausea and vomiting during pregnancy. ... It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. ... Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects [L6220], belonging …

Pramipexole

Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Description: … agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and ... Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of …

Meclizine

Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in...
Approved
Matched Description: … Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. ... It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. ... It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular …

Rotigotine

Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and …

Grepafloxacin

Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Approved
Investigational
Withdrawn
Matched Description: … QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and …

Lomefloxacin

Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Approved
Investigational
Matched Description: … Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and …

Brigatinib

Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Description: … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and ... Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Ethambutol

Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and …
Matched Categories: … ethambutol and isoniazid ... rifampicin, ethambutol and isoniazid ... rifampicin, pyrazinamide, ethambutol and isoniazid …

Clemastine

An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Matched Description: … ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and …

Viloxazine

Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Matched Description: … the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and ... designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and …

Infigratinib

Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Description: … [A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 451 - 475 of 14791 in total